Overview
Cronos Q2 2025 net revenue grows 21% yr/yr, misses analyst expectations
Gross profit rises significantly due to higher sales prices and efficiencies
Co reports net loss of $38.5 mln, impacted by foreign exchange losses
Outlook
Cronos expects accelerated growth in H2 2025
Company anticipates sales boost from Cronos GrowCo expansion in Fall 2025
Company sees positive impact from anti-dumping duty veto in Israel
Result Drivers
INTERNATIONAL DEMAND - Record international and Israel revenue driven by strong global demand for cannabis products
CRONOS GROWCO CONTRIBUTION - Consolidation of Cronos GrowCo added $2.2 mln to Q2 2025 net revenue
ISRAEL MARKET - Record revenue and sales volume in Israel driven by strong demand for high-quality medical cannabis and effective operations, per CEO Mike Gorenstein
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Miss | $2.21 mln | $32.90 mln (1 Analyst) |
Q2 Net Income |
| -$38.48 mln |
|
Q2 Adjusted EBITDA |
| $1.69 mln |
|
Q2 Gross Margin |
| 43.0% |
|
Q2 Capex |
| $3.84 mln |
|
Q2 Gross Profit |
| $14.50 mln |
|
Analyst Coverage
The one available analyst rating on the shares is "buy"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Press Release: ID:nGNX880CYb